Home LiteratureArticle Details
PMID: 1370092 Published · ppublish English Journal Article

Identification of VP7 epitopes associated with protection against human rotavirus illness or shedding in volunteers.

Journal of virology ·Vol. 66 ·No. 1 ·1992-01-00 ·Pages 548-53

Green KY, Kapikian AZ

Abstract

Sera from 17 of 18 adult volunteers challenged with a virulent serotype 1 rotavirus strain (D) were examined for prechallenge antibody levels against several well-defined rotavirus VP7 and VP4 neutralization epitopes by a competitive epitope-blocking immunoassay (EBA) in order to determine whether correlates of resistance to diarrheal illness could be identified. The presence of prechallenge serum antibody at a titer of greater than or equal to 1:20 that blocked the binding of a serotype 1 VP7-specific monoclonal antibody (designated 2C9) that maps to amino acid residue 94 in antigenic site A on the serotype 1 VP7 was significantly associated with resistance to illness or shedding (P less than 0.001) or illness and shedding (P less than 0.01) following challenge with the serotype 1 virus. In addition, an EBA antibody titer of greater than or equal to 1:20 in prechallenge serum against a serotype 3 VP7-specific epitope (defined by monoclonal antibody 954/159) that maps to amino acid 94 on the serotype 3 VP7 was also significantly associated with resistance to illness or shedding (P = 0.02), with a trend for protection against illness and shedding. A trend was also noted between the presence of EBA antibody against a cross-reactive VP4 epitope common to many human rotavirus strains, including the challenge virus, or a rhesus monkey rotavirus strain-specific VP4 antigenic site, and resistance to illness or shedding. These data confirm that the presence of serum antibody correlates with resistance to rotavirus illness or shedding but, in addition, demonstrate the association of antibody to a specific epitope with resistance to illness or shedding. These data also suggest that antigenic site A on the rotavirus VP7, composed of amino acids 87 to 96, may be involved in the formation of a major protective epitope. Further study of the role of this epitope in the development of homotypic and heterotypic immunity to rotaviruses following natural or vaccine-induced infection may be important in the development of strategies for control of rotavirus diarrheal disease.

MeSH Terms
Adult Antibodies, Viral/blood,immunology Antigens, Viral Capsid/immunology Capsid Proteins Diarrhea/blood,immunology Epitopes/blood,immunology Humans Immunity, Innate/immunology Immunoassay Neutralization Tests Rotavirus/immunology Rotavirus Infections/immunology Serotyping Viral Plaque Assay
Chemicals
Antibodies, Viral Antigens, Viral Capsid Proteins Epitopes VP7 protein, Rotavirus
Authors & Affiliations
2 authors, click to expand affiliations / ORCID
Green K Y
Epidemiology Section, National Institute of Allergy and Infectious Diseases, Bethesda, Maryland 20892.
Kapikian A Z
References (41)
41 references, click to expand
  1. Studies in volunteers with human rotaviruses.
    Dev Biol Stand. 1983;53:209-18 PMID: 6307776
  2. Live attenuated oral rotavirus vaccine.
    Lancet. 1987 Nov 7;2(8567):1091-2 PMID: 2890003
  3. Protective effect of naturally acquired homotypic and heterotypic rotavirus antibodies.
    Lancet. 1986 Aug 23;2(8504):417-21 PMID: 2874413
  4. Trial of an attenuated bovine rotavirus vaccine (RIT 4237) in Gambian infants.
    Lancet. 1987 Jun 13;1(8546):1342-5 PMID: 2884455
  5. Rotavirus: the major etiologic agent of severe infantile diarrhea may be controllable by a "Jennerian" approach to vaccination.
    J Infect Dis. 1986 May;153(5):815-22 PMID: 3009632
  6. Preliminary evaluation of the efficacy of rhesus rotavirus vaccine strain MMU 18006 in young children.
    Pediatr Infect Dis. 1986 Sep-Oct;5(5):587-8 PMID: 3020521
  7. Safety and immunogenicity of live attenuated rhesus monkey rotavirus vaccine.
    J Infect Dis. 1986 Dec;154(6):1045-7 PMID: 3023497
  8. Protection of infants against rotavirus diarrhoea by RIT 4237 attenuated bovine rotavirus strain vaccine.
    Lancet. 1984 May 5;1(8384):977-81 PMID: 6143964
  9. Antigenic characterization of human and animal rotaviruses by immune adherence hemagglutination assay (IAHA): evidence for distinctness of IAHA and neutralization antigens.
    Infect Immun. 1981 Aug;33(2):415-25 PMID: 6168588
  10. Oral administration of human rotavirus to volunteers: induction of illness and correlates of resistance.
    J Infect Dis. 1983 Jan;147(1):95-106 PMID: 6296243
  11. Induction of cross-reactive serum neutralizing antibody to human rotavirus in calves after in utero administration of bovine rotavirus.
    J Clin Microbiol. 1983 Sep;18(3):505-8 PMID: 6313744
  12. Rotaviral immunity in gnotobiotic calves: heterologous resistance to human virus induced by bovine virus.
    Science. 1979 Feb 9;203(4380):548-50 PMID: 216077
  13. Serotype-specific epitope(s) present on the VP8 subunit of rotavirus VP4 protein.
    J Virol. 1991 Jun;65(6):3213-8 PMID: 1709699
  14. Rhesus Rotavirus candidate vaccine. Clinical trial in children vaccinated between 2 and 5 months of age.
    Am J Dis Child. 1990 Mar;144(3):285-9 PMID: 2154925
  15. Prospective study of diarrheal diseases in Venezuelan children to evaluate the efficacy of rhesus rotavirus vaccine.
    J Med Virol. 1990 Mar;30(3):219-29 PMID: 2160516
  16. Evaluation of RIT 4237 bovine rotavirus vaccine in newborn infants: correlation of vaccine efficacy to season of birth in relation to rotavirus epidemic period.
    Scand J Infect Dis. 1990;22(3):269-78 PMID: 2164706
  17. Effect of vaccination on serotype-specific antibody responses in infants administered WC3 bovine rotavirus before or after a natural rotavirus infection.
    J Infect Dis. 1990 Dec;162(6):1298-303 PMID: 2172404
  18. Location of the major antigenic sites involved in rotavirus serotype-specific neutralization.
    Proc Natl Acad Sci U S A. 1986 May;83(10):3465-8 PMID: 2422651
  19. Derivation of neutralizing monoclonal antibodies to human rotaviruses and evidence that an immunodominant neutralization site is shared between serotypes 1 and 3.
    Virology. 1986 Oct 30;154(2):302-12 PMID: 2429439
  20. Cross-reactive and serotype-specific neutralization epitopes on VP7 of human rotavirus: nucleotide sequence analysis of antigenic mutants selected with monoclonal antibodies.
    J Virol. 1988 Jun;62(6):1870-4 PMID: 2452893
  21. Characterization of homotypic and heterotypic VP7 neutralization sites of rhesus rotavirus.
    Virology. 1988 Aug;165(2):511-7 PMID: 2457279
  22. Prolonged efficacy of rhesus rotavirus vaccine in Swedish children.
    J Infect Dis. 1989 Apr;159(4):753-7 PMID: 2538521
  23. Strategies for the development of a rotavirus vaccine against infantile diarrhea with an update on clinical trials of rotavirus vaccines.
    Adv Exp Med Biol. 1989;257:67-89 PMID: 2559615
  24. Prediction of human rotavirus serotype by nucleotide sequence analysis of the VP7 protein gene.
    J Virol. 1988 May;62(5):1819-23 PMID: 2833626
  25. A field study of the safety and efficacy of two candidate rotavirus vaccines in a Native American population.
    J Infect Dis. 1991 Mar;163(3):483-7 PMID: 1995721
  26. Passive immunity in rotaviral infections.
    J Am Vet Med Assoc. 1978 Sep 1;173(5 Pt 2):565-8 PMID: 212400
  27. Field trial of rhesus rotavirus vaccine in infants.
    Pediatr Infect Dis J. 1988 Sep;7(9):645-50 PMID: 2845349
  28. Homotypic and heterotypic epitope-specific antibody responses in adult and infant rotavirus vaccinees: implications for vaccine development.
    J Infect Dis. 1990 Apr;161(4):667-79 PMID: 2156942
  29. Evaluation of WC3 rotavirus vaccine and correlates of protection in healthy infants.
    J Infect Dis. 1990 Nov;162(5):1055-62 PMID: 2172394
  30. An efficacy trial of the rhesus rotavirus vaccine in Maryland. The Clinical Study Group.
    Am J Dis Child. 1990 May;144(5):601-4 PMID: 2330930
  31. Epitope-specific immune responses to rotavirus vaccination.
    Gastroenterology. 1987 Nov;93(5):941-50 PMID: 2443417
  32. Identification of cross-reactive and serotype 2-specific neutralization epitopes on VP3 of human rotavirus.
    J Virol. 1988 Jul;62(7):2421-6 PMID: 2453680
  33. Protection of Peruvian children against rotavirus diarrhea of specific serotypes by one, two, or three doses of the RIT 4237 attenuated bovine rotavirus vaccine.
    J Infect Dis. 1989 Mar;159(3):452-9 PMID: 2536789
  34. Reassortant rotaviruses containing structural proteins vp3 and vp7 from different parents induce antibodies protective against each parental serotype.
    J Virol. 1986 Nov;60(2):491-6 PMID: 3021983
  35. Clinical efficacy of the RIT 4237 live attenuated bovine rotavirus vaccine in infants vaccinated before a rotavirus epidemic.
    J Pediatr. 1985 Aug;107(2):189-94 PMID: 3894608
  36. Definition of human rotavirus serotypes by plaque reduction assay.
    Infect Immun. 1982 Jul;37(1):110-5 PMID: 6286487
  37. Infection immunity of piglets to either VP3 or VP7 outer capsid protein confers resistance to challenge with a virulent rotavirus bearing the corresponding antigen.
    J Virol. 1988 Mar;62(3):744-8 PMID: 2828669
  38. Protective effect of WC3 vaccine against rotavirus diarrhea in infants during a predominantly serotype 1 rotavirus season.
    J Infect Dis. 1988 Sep;158(3):570-87 PMID: 2842405
  39. Failure of live, attenuated oral rotavirus vaccine.
    Lancet. 1986 Jul 12;2(8498):108 PMID: 2873370
  40. Protection against severe rotavirus diarrhoea by rhesus rotavirus vaccine in Venezuelan infants.
    Lancet. 1987 Apr 18;1(8538):882-4 PMID: 2882289
  41. Human-rhesus reassortant rotavirus vaccines: safety and immunogenicity in adults, infants, and children.
    J Infect Dis. 1988 Dec;158(6):1261-7 PMID: 2848902
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
Published
1992-01-00
Pages
548-53
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC238315
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com